Cross-Sector entity
Of the tracked stories, 5 of 8 also mention Johnson & Johnson, the most common co-covered peer. The 110-day window averages about 0.5 stories each week. The busiest single day carried 3. The clearest coverage concentration is market-trends: 3 of 8 stories, with the rest divided among 4 other categories.
8 verified stories tracked
Last mentioned: Jun 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 5 of 8 also mention Johnson & Johnson, the most common co-covered peer. The 110-day window averages about 0.5 stories each week. The busiest single day carried 3. The clearest coverage concentration is market-trends: 3 of 8 stories, with the rest divided among 4 other categories. We currently track 8 Cross-Sector stories that mention Protagonist Therapeutics, published between February 25, 2026 and June 14, 2026. 0% of these stories carry negative sentiment. The tracked stories average 2 original sources each.
Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protagonist Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
Quarterly Earnings Release
Official financial results and conference calls scheduled for both companies.
Pre-Earnings Market Activity
Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
Takeda Deal Restructuring
Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
VERIFY Enrollment
Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
J&J Milestone
Protagonist receives $231M milestone payment for icotrokinra progress.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Source: Equity Eagle · Equity Eagle
Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Source: themarketsdaily.com · tickerreport.com
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
